In an exploratory trial involving patients with anti PD-1 refractory GI cancers (including gastric, esophageal, and liver cancers), administering FMT from a donor (followed by anti PD-1 rechallenge) achieved an objective response rate of ~20% and a disease control rate of 95% (115, 116). Here, PDCD1 is linked to liver cancer.